Abiraterone Acetate - Zytiga

On April 28, 2011, the US Food and Drug Administration (FDA) approved Zytiga (abiraterone acetate), for use in combination with prednisone for the second-line treatment of castration-resistant prost...

Sanofi-Aventis

Sanofi-Aventis is a global pharmaceutical company with annual sales of $40,871m, placing it the second highest in the world. Although Sanofi-Aventis products are for a a very wide range of health...

Human medicines European Public Assessment Report (EPAR): Taxotere, docetaxel, Revision: 32, Authorised

Human medicines European Public Assessment Report (EPAR): Taxotere, docetaxel, Revision: 30, Authorised

Bristol’s Taxol, Sanofi’s Taxotere Among Latest Victims Of China Price Cuts

China’s NDRC cuts retail ceiling prices on 95 cancer, hematology and immunology drugs, with more cuts expected next year.

OncoGenex: SYNERGY Trial Is The Major Catalyst In Sight

ByBiomed Group:OncoGenex (OGXI) is a development-stage biopharmaceutical company focused on new cancer therapies to address treatment resistance in cancer patients. OncoGenex's lead compound, custirse...

Platinum Doublet Effective in NSCLC (CME/CE)

ATLANTA (MedPage Today) -- The combination of docetaxel (Taxotere) and oxaliplatin appears to be effective in patients with advanced or metastatic non-small cell lung cancer (NSCLC), researchers repor...

Aussie Pharmacists Admit $202 Million In Annual Drug Overcharges

Australian pharmacists acknowledged U.S.$202 million worth of annual overcharges for chemotherapy drugs, primarily for the generic version of Sanofi's Taxotere (docetaxel).

Genentech Gets FDA Approval for Combo Treatment

Xconomy | Genentech announced early results of a new drug targeting HER2-expressing cancers early last week, and later received FDA approval to market Perjeta in combination with Herceptin and Taxot...

FDA approves androgen inhibitor for metastatic PCa

The FDA recently approved the oral androgen receptor inhibitor enzalutamide (Xtandi) for the treatment of patients with metastatic castration-resistant prostate cancer who have previously received...

Development of docetaxel-loaded intravenous formulation, Nanoxel-PM™ using polymer-based delivery system.

Nanoxel-PM™, docetaxel-loaded methoxy-poly(ethylene glycol)-block-poly(d,l-lactide) (mPEG-PDLLA) micellar formulation was prepared in an effort to develop alternative, less toxic and efficacious Twe...

Stable and efficient delivery of docetaxel by micelle-encapsulation using a tripodal cyclotriphosphazene amphiphile.

Docetaxel micelle-encapsulated by a tripodal cyclotriphosphazene amphiphilile [NP(PEG750)(GlyPheLeu)(2)Et](3) (CP750) exhibited outstanding drug-loaded micelle stability in aqueous solution compared w...

Clinical and Histopathologic Correlation of an Eruption Secondary to Taxotere.

Eruptions in cancer patients may signal life-threatening infections, cutaneous metastases or reactions to chemotherapeutic agents. Distinguishing between these processes is essential to correctly trea...

Pharmacokinetics, Efficacy, and Safety Evaluation of Docetaxel/Hydroxypropyl-Sulfobutyl-β-Cyclodextrin Inclusion Complex.

Hydroxypropyl-sulfobutyl-β-cyclodextrin (HP-SBE-β-CD) inclusion complex was developed and used as a drug delivery system for DTX (DTX/HP-SBE-β-CD). The objective of the present study was to evaluat...

Properties and effects of a novel liquid crystal nanoparticle formulation of docetaxel in a prostate cancer mouse model.

Treatment with docetaxel is the standard of care as first line chemotherapy in castration resistant prostate cancer. Due to serious side effects from the commercially available Taxotere formulation, w...